Sacituzumab Govitecan in Recurrent Glioblastoma

This study tests sacituzumab govitecan — an antibody-drug that delivers chemotherapy directly to cancer cells — for patients with glioblastoma (GBM) whose brain tumor has come back after initial treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with recurrent glioblastoma (a primary brain cancer) confirmed by biopsy - Your tumor is IDH wild-type (the most common and aggressive form) - You have already received standard radiation therapy and, if applicable, chemotherapy - If you had surgery for recurrence, it must be at least 2 weeks before starting this study **You may NOT be eligible if...** - Your tumor has an IDH mutation (a different subtype) - You have received more than one additional line of therapy after your initial treatment - You have had radiotherapy within the past 3 months - You are not stable enough to stop steroids or reduce them - You have significant other medical conditions affecting your safety Talk to your doctor to see if this trial is right for you.